← Compound index
RESEARCH FAMILY / GLYPROLINS

Glyprolins & PGP hybridsГлипролины

A family of short peptides rich in glycine and proline, including PGP and experimental peptides built by adding PGP to another sequence.

CognitionRecovery
Source linked

What the studies found

Animal research · 2006

Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis

Female offspring
Authors report prevention of the measured negative behavioral consequences
Male offspring: residual deficit
Most measured effects improved, but delayed physical development persisted

Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.

Study notes · methods, sources and limitations

Participants or model Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract

Design Intranasal Pro-Gly-Pro to pups on postnatal days 13–15, 1 mg/kg; adult physical development, spontaneous behavior and training evaluated.

Important limitations

  • Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
  • Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety. Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.

Bulletin of experimental biology and medicine. 2006;142(1):32-4. PMID 17369896 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Lab research · 2017

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

Study of multiple preparations

Selank neuronal differentiation
GABA-positive neuron ratio decreased by 61%Selank 100 µM versus control; not an in-vivo malformation endpoint
PGP proliferation
Small but significant inhibition at 10 µMNo numerical inhibition magnitude in abstract
Semax cell survival
Increased survival at 10 and 0.1 µM during serum deprivationCell-stress endpoint, not reproductive toxicology

Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.

More reported outcomes
Safety-inference limit
The authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy
Study notes · methods, sources and limitations

Participants or model Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses

Design Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.

Important limitations

  • Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
  • Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333 · Original journal publication

Original source or citation ↗

Study results and tables ↗

Animal research · 2014

[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].

PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.

Study notes · methods, sources and limitations

Participants or model Rat cortical tissue at 3 and 24 hours after permanent focal ischemia

Important limitations

  • PGP was tested separately; results cannot be assigned wholesale to Semax or Selank. Gene-expression endpoints do not establish clinical stroke efficacy.

Molekuliarnaia biologiia; 2014 · Indexed abstract

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Glyprolins & PGP hybrids

Names in this research collection

PGP · Pro-Gly-Pro · PG · GP · PGPL · Gly-Hyp · Pro-Hyp-Gly · Gly-Pro-Hyp · Gly-Hyp-Pro · Hyp-Gly-Pro · GHyp · PHypG · GPHyp · GHypP · HypGP · GPE

Research background

A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.

Pregnancy and offspring research

Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.

Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.

Reported findings and methods ↗ · Pregnancy research: full evidence review and archive ↗

Compound class
Peptide research family
Research collection
Neuropeptide research · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

No human treatment trial assessed for this family

Study methods

Member-specific studies; patents and archival leads identified separately

Independent replication

Independent replication not established by the records collected here

Source access

Primary abstracts, selected full texts, patents and explicit retrieval targets

Safety evidence

Cell and animal effects do not establish human safety; analogues may differ

Open a topic for the evidence assessment.

More findings, background and history
IDENTITY / MEMBER-SPECIFIC EVIDENCE

Inside this research family

Grouping supports navigation. It does not imply equivalent composition, mechanisms, effectiveness or safety.

Research objects, findings and source boundaries
MemberIdentityWhat the source supports
PGP / PG / GPLinear glyprolin core

Historical developer literature motivates both stability and regulatory-function research.

Natural and hybrid ("chimeric") stable regulatory glyproline peptides. ↗

PGPLPro-Gly-Pro-Leu

Gene-expression effects after rat ischemia differed from Semax.

Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion. ↗

Semax / SelankDistinct PGP-containing hybrid peptides

A shared tail is not evidence of interchangeable effects or source identity.

Natural and hybrid ("chimeric") stable regulatory glyproline peptides. ↗

Hydroxyproline sequencesGHyp, PHypG, GPHyp, GHypP, HypGP

Classification and collagen-fragment leads; individual Russian pharmacology requires source recovery.

Original-source recovery pending

Interpretation and open questions

Collagen/elastin breakdown is a proposed source for parts of this family; it is not proven provenance for every listed molecule.

The direct Semax/PGP/PGPL comparison is retained because its differences are more informative than a blanket claim of glyprolin neuroprotection.

Explore the Russian peptide research map ↗

Stroke research matrix ↗ — compare human stroke outcomes, experimental findings, safety and adjacent cerebral-ischemia research.

What remains unclear

The available experimental studies leave human benefit and safety uncertain.

No human intervention report has been identified among the linked records; unclassified archival leads may remain. Several publications can describe the same participants.

Browse original study records ↗
PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2018 · RU2646604C2 · GZK-111: N-phenylacetyl glyprolin derivativesMolecule · CPG formation observed during incubation with plasma and brain homogenate

Findings described in words

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Metabolic identity
CPG formation observed during incubation with plasma and brain homogenateSupports a precursor/metabolite relationship; not a human clinical exposure estimate
Cell-injury comparison
Concentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell modelNo quantitative cell-survival percentage independently transcribed
All reported results, comparisons and limitations →

Molecule. The claimed class includes phenylacetylglycyl-L-proline ethyl ester, alongside other stereochemical and terminal variants.

The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.

Publication
RU2646604C2 ↗ · 2018-03-06
Earliest priority / filing
2016-01-12 / 2016-01-12
Original applicant / assignee
Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
59497169 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Novel glyprolins with nootropic, anti-hypoxic, neuroprotective and anssiylitis activity

Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Ксения Николаевна Колясникова; Елена Александровна Кузнецова; Татьяна Александровна Воронина; Милада Альнордовна Яркова; Татьяна Алексеевна Антипова; Светлана Александровна Литвинова; Николай Николаевич Золотов.

RU2646604C2

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Animal research · 2006

Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis

Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.

Study notes and original source
2006Animal / experimentalEnglish abstract

Peptidergic correction of behavior in adult progeny of albino rats exposed to acute hypoxia during early organogenesis

glyprolins · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Graf AV, Maklakova AS, Krushinskaya YV, Sokolova NA · Bulletin of experimental biology and medicine. 2006;142(1):32-4. PMID 17369896

Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.

Results and tables

Reported findings and study design

Findings described in words

Postnatal Pro-Gly-Pro reportedly prevented delayed behavioral effects in adult females and most effects in males. Delayed physical development persisted in males. The mothers were not given PGP in this experiment.

Intranasal Pro-Gly-Pro to pups on postnatal days 13–15, 1 mg/kg; adult physical development, spontaneous behavior and training evaluated.

Population or model Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract

Dose, route and schedule

Pro-Gly-Pro 1 mg/kg intranasally to pups on postnatal days 13–15, following maternal hypoxia on gestation days 9–10. Research description, not human-use advice.

Protocol source ↗ · Indexed original abstract; full methods and outcome tables not recovered

Results · Indexed original abstract; full methods and outcome tables not recovered
MeasureResultComparison, timing and statistics
Female offspringAuthors report prevention of the measured negative behavioral consequences
Male offspring: residual deficitMost measured effects improved, but delayed physical development persisted

Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety. Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Rat offspring exposed to hypoxia on gestation days 9–10; n unavailable in abstract
Source reviewed
Indexed original abstract; full methods and outcome tables not recovered
Study limitations
  • Treatment was given to offspring after birth; this does not test maternal PGP exposure or fetal safety.
  • Sample sizes, numerical scores, masking and litter-level analyses unavailable in the abstract. Sex-specific qualitative results are not quantified effect estimates.

Reviewed 2026-11-08.

Read the source ↗

Lab research · 2017

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.

Study notes and original source
2017In vitroEnglish abstract

Studying the Toxic Effects of Some Biologically Active Peptides on the Model of Mouse Embryonic Stem Cells

semax, selank, glyprolins · Original journal publication

Format: Publication record and available text · Reviewed: Indexed original abstract; full methods and outcome tables not recovered

Kobylyanskii AG, Zolotarev YA, Andreeva LA, Grivennikov IA, Myasoedov NF · Bulletin of experimental biology and medicine. 2017;163(6):731. PMID 29063333

Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.

Results and tables

Reported findings and study design

Reported findings

Selank at 100 µM reduced the GABA-positive neuron ratio by 61% versus control. Semax improved cell survival under serum deprivation, while PGP modestly inhibited proliferation at 10 µM. Cell findings cannot substantiate the abstract’s broad fetal-safety conclusion.

Cultured mouse embryonic stem cells; proliferation, survival during serum deprivation and neuronal differentiation after several peptides and growth-factor controls.

Population or model Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses

Results · Indexed original abstract; full methods and outcome tables not recovered
MeasureResultComparison, timing and statistics
Selank neuronal differentiationGABA-positive neuron ratio decreased by 61%Selank 100 µM versus control; not an in-vivo malformation endpoint
PGP proliferationSmall but significant inhibition at 10 µMNo numerical inhibition magnitude in abstract
Semax cell survivalIncreased survival at 10 and 0.1 µM during serum deprivationCell-stress endpoint, not reproductive toxicology
Safety-inference limitThe authors infer no embryonic/fetal toxicity; this culture model does not establish that claim in pregnancy

Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes. The study also found reduced cell differentiation and proliferation. Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Source for these results ↗ · Reviewed 2026-11-08

Population / setting
Mouse embryonic stem cells and neuronal derivatives, not pregnant animals or human fetuses
Source reviewed
Indexed original abstract; full methods and outcome tables not recovered
Study limitations
  • Embryonic-cell experiments do not test placental exposure, whole-embryo development, birth defects or pregnancy outcomes.
  • The study also found reduced cell differentiation and proliferation.
  • Concentrations in a culture dish are not human doses; biological replicate counts and complete numerical results absent from the abstract.

Reviewed 2026-11-08.

Read the source ↗

Experiment described in a patent · 2018

GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Study notes and original source
2018Patent / reported experimentsFull text available

GZK-111: N-phenylacetyl glyprolin derivatives — RU2646604C2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Сергей Борисович Середенин, Татьяна Александровна Гудашева, Ксения Николаевна Колясникова, Елена Александровна Кузнецова, Татьяна Александровна Воронина, Милада Альнордовна Яркова, Татьяна Алексеевна Антипова, Светлана Александровна Литвинова, Николай Николаевич Золотов · RU2646604C2 · patent family 59497169

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

Results and tables

Reported patent results

Findings described in words

The disclosure reports conversion of GZK-111 to CPG and activity in selected preclinical models.

GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.

Population or model GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.

Results · Experimental metabolism, cell-injury and behavioral/hypoxia summaries.
MeasureResultComparison, timing and statistics
Metabolic identityCPG formation observed during incubation with plasma and brain homogenateSupports a precursor/metabolite relationship; not a human clinical exposure estimate
Cell-injury comparisonConcentration-dependent neuroprotection reported for GZK-111 in the neuronal-cell modelNo quantitative cell-survival percentage independently transcribed
Animal findingsIncreased survival time under experimental hypoxia and anxiolytic-like behavioral findings reported at selected exposuresDifferent compounds and assays must not be pooled

These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
GZK-111/GZK-113 experimental program: metabolism assays, neuronal-cell injury and animal behavioral/hypoxia tests.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The precursor and cyclic metabolite CPG are different molecules. A broad class is not a patent match to every glyprolin or to the similarly named GZS-411.
  • These results do not establish human cognition or anxiety treatment and cannot be transferred to GZS-411. GZK-111 is distinct from its cyclic metabolite CPG.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Animal research · 2014

[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].

PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.

Study notes and original source
2014Animal / experimentalEnglish abstract

[Effect of tripeptide Pro-Gly-Pro on rat brain transcriptome in focal ischemia].

Medvedeva EV, Dmitrieva VG, Povarova OV, Limborskaia SA, Skvortsova VI, Miasoedov NF, Dergunova LV · Molekuliarnaia biologiia; 2014

PGP altered expression of 29 genes at three hours and 57 at 24 hours; immune-response genes were predominantly downregulated at the later time point.

Population / setting
Rat cortical tissue at 3 and 24 hours after permanent focal ischemia
Source reviewed
Indexed primary-publication abstract checked; full methods not appraised.
Study limitations
  • PGP was tested separately; results cannot be assigned wholesale to Semax or Selank.
  • Gene-expression endpoints do not establish clinical stroke efficacy.

Reviewed 2026-10-11.

Read the source ↗

Review of earlier studies · 2005

Natural and hybrid ("chimeric") stable regulatory glyproline peptides.

The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.

Study notes and original source
2005ReviewEnglish abstract

Natural and hybrid ("chimeric") stable regulatory glyproline peptides.

Ashmarin IP, Samonina GE, Lyapina LA, Kamenskii AA, Levitskaya NG, Grivennikov IA, Dolotov OV, Andreeva LA, Myasoedov NF · Pathophysiology : the official journal of the International Society for Pathophysiology

The developers described PGP-containing hybrid peptides as a way to combine regulatory activity with greater peptide stability. This historical framework does not transfer Semax or Selank outcomes to isolated PGP.

Population / setting
Developer synthesis of glyprolin research
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Review of a research program, not an independent trial.
  • Specific peptide origin, metabolism and clinical claims require original-source confirmation.

Reviewed 2026-10-05.

Read the source ↗

Animal research · 2022

Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.

PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.

Study notes and original source
2022Animal / experimentalEnglish abstract

Insight into Glyproline Peptides' Activity through the Modulation of the Inflammatory and Neurosignaling Genetic Response Following Cerebral Ischemia-Reperfusion.

Stavchansky VV, Filippenkov IB, Remizova JA, Denisova AE, Mozgovoy IV, Gubsky LV, Myasoedov NF, Andreeva LA, Limborska SA, Dergunova LV · Genes

PGP and PGPL did not reproduce Semax’s gene-expression response after cerebral ischemia in rats. Most measured genes remained unchanged with the shorter peptides, underscoring that a shared PGP motif does not imply equivalent effects.

Population / setting
Rat transient middle cerebral artery occlusion; gene-expression assays
Source reviewed
Primary publication metadata and indexed abstract checked via Europe PMC; full methodological review pending.
Study limitations
  • Preclinical findings do not establish human benefit or safety.
  • Abstract only. Full methods and independent replication remain unconfirmed.

Reviewed 2026-10-05.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗